Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Top Cited Papers
Open Access
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Cell
- Vol. 161 (2), 205-214
- https://doi.org/10.1016/j.cell.2015.03.030
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Mutations of the BRAF gene in human cancerNature, 2002
- T-cell antigen receptor genes and T-cell recognitionNature, 1988